- Danish biotech Visibuilt has raised €3.34 million in a seed round co-led by EIFO and Unconventional Ventures, with Proptechfonden and returning investor EMDFonden also participating.
- The startup’s visiBINDER is a mycelium-based binder designed to replace fossil bitumen and cement in roads and pavers — materials responsible for a meaningful share of the EU’s estimated €83 billion annual spend on fossil-based asphalt binder alone.
- Visibuilt has already locked in industrial testing partnerships with Denmark’s largest concrete paver manufacturer, IBF, and Copenhagen Municipality, less than two years after founding.
Line Kloster Pedersen was running around Copenhagen’s lakes when she looked down at the soil and wondered why cities still glue roads together with oil, when fungi have been binding earth for millions of years. That question now has €3.34 million behind it.
Today, Visibuilt, the biotech she founded in 2023 with Oleksii Rebrov, has closed a €3.34 million seed round co-led by EIFO, Denmark’s state investment and export fund, and Unconventional Ventures, with participation from Proptechfonden and returning backer EMDFonden.
What visiBINDER replaces
Visibuilt’s core product, visiBINDER, is a binder fermented from mycelium, the underground root network of fungi, designed to replace bitumen and cement in paving and infrastructure.
Conventional asphalt production runs at temperatures up to 250°C; the company says its fermentation-based process can bind aggregate at near-room temperature, cutting both energy use and manufacturing emissions.
The technology has already moved off the lab bench. Visibuilt has partnered with contractors NCC and Munck Asfalt to trial the binder under real road conditions and, more recently, entered into a strategic partnership with concrete paver manufacturer IBF to develop visiPAVER, an outdoor paver bound with visiBINDER instead of cement.
IBF is, by its own description, Denmark’s leading producer of concrete paving products, which makes the tie-up a meaningful validation step for a binder that still has to prove itself against a century-old incumbent. Visibuilt has also worked with Copenhagen Municipality on testing.
The company is headquartered at the Alfa Laval Innovation House near Copenhagen, with labs and pilot facilities also based at the Danish Technological Institute, and employs roughly 18 people.
“Closing this seed round enables us to mature our technical platform, validate our solution at a larger scale and take the next steps towards the market,” Pedersen says.
Why is a mycelium binder different from mycelium construction
Visibuilt sits in a crowded and increasingly well-funded field of startups trying to decarbonise construction materials, but its angle is narrower than most.
UK-based Material Evolution has raised £15 million to scale low-carbon cement made from industrial waste, and Sweden’s Cemvision closed a €10 million seed round backed by Bill Gates’ Breakthrough Energy to reformulate Portland cement itself. Bristol’s Mykor raised £4 million to bring a fungi-grown structural insulation panel to market, bringing its own total to £7.5 million. US-based Prometheus Materials and Canada’s CarbiCrete are pursuing microalgae- and CO2-cured concrete, respectively.
Most of that competition is re-engineering cement or concrete itself. Visibuilt is instead targeting the binder layer that sits beneath both cement and bitumen, a narrower slice of the embodied-carbon problem, but one that in principle lets contractors keep their existing plants and paving equipment rather than requiring new factories.
Denmark also has form here: Mycoverse, a DTU spin-out, raised €2.4 million to apply fungi to crop protection, part of a broader Danish pattern of fermentation-based biotech attracting early institutional capital.
Sara Sande, managing director, partner, and head of Direct Thematic Venture at EIFO, says concrete and asphalt production are among the largest sources of CO2 emissions globally, and that reducing emissions in heavy industry requires entirely new solutions.
Thea Messel, general partner at Unconventional Ventures, points to Visibuilt’s early commercial traction as the reason the fund co-led: securing testing partnerships with IBF and Copenhagen Municipality within two years of founding, without a finished production line or a fully derisked product, is, in her framing, an unusual execution signal for a hard-tech founder at this stage.
The market, and the obstacle that no funding round can remove
Bio-based building materials are forecast to grow from roughly $34 billion in 2025 to nearly $195 billion by 2035, at a compound annual growth rate of nearly 19%, according to Future Market Insights. That growth is being pulled forward by tightening embodied-carbon rules across Europe, the same regulatory pressure driving investment into Mykor, Cemvision and Material Evolution alike.
The harder problem is regulatory rather than technical. The EU currently has no standard for asphalt that doesn’t use an oil-based binder, and construction is one of the most conservative, safety-regulated industries in existence — new paving materials are expected to prove decades of durability before anyone will put them under daily traffic.
Visibuilt still needs a path to CE marking before visiBINDER can move from parking lots and bike paths to actual roads, and Kloster Pedersen has previously said the absence of an EU standard is itself a live obstacle to commercialisation.
The new capital will go toward large-scale industrial validation with Visibuilt’s existing partners, expanding production capacity for bigger trials, and growing the technical and commercial team.
Whether a fungus can survive freeze-thaw cycles and a decade of traffic, as bitumen has for a century, is the question that will decide whether this becomes an industrial material or remains a well-funded demonstration.